[go: up one dir, main page]

RU2003105159A - METHOD FOR TREATING CLIMACTERIC DISORDERS IN WOMEN DURING OR AFTER MENOPAUSE - Google Patents

METHOD FOR TREATING CLIMACTERIC DISORDERS IN WOMEN DURING OR AFTER MENOPAUSE

Info

Publication number
RU2003105159A
RU2003105159A RU2003105159/14A RU2003105159A RU2003105159A RU 2003105159 A RU2003105159 A RU 2003105159A RU 2003105159/14 A RU2003105159/14 A RU 2003105159/14A RU 2003105159 A RU2003105159 A RU 2003105159A RU 2003105159 A RU2003105159 A RU 2003105159A
Authority
RU
Russia
Prior art keywords
ester
compound
salt
menopause
administered
Prior art date
Application number
RU2003105159/14A
Other languages
Russian (ru)
Other versions
RU2268035C2 (en
Inventor
Кайя ХАЛОНЕН
Лаури КАНГАС
Майкл В. ДЕГРЕГОРИО
Original Assignee
Хормос Медикал Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/625,199 external-priority patent/US6245819B1/en
Application filed by Хормос Медикал Корпорейшн filed Critical Хормос Медикал Корпорейшн
Publication of RU2003105159A publication Critical patent/RU2003105159A/en
Application granted granted Critical
Publication of RU2268035C2 publication Critical patent/RU2268035C2/en

Links

Claims (8)

1. Способ лечения сухости влагалища или половой дисфункции у женщин во время или после менопаузы, причем указанный способ включает введение женщине эффективного количества соединения (деаминогидрокси)торемифена или его фармацевтически приемлемой соли или сложного эфира или метаболита.1. A method for treating vaginal dryness or sexual dysfunction in women during or after menopause, said method comprising administering to a woman an effective amount of a toremifene compound (deaminohydroxy) or a pharmaceutically acceptable salt or ester or metabolite thereof. 2. Способ по п.1, в котором соединение, или его соль, или сложный эфир вводят в суточной дозе, варьирующей в диапазоне от 25 до 100 мг.2. The method according to claim 1, in which the compound, or its salt, or ester is administered in a daily dose ranging from 25 to 100 mg. 3. Способ по п.2, в котором соединение, или его соль, или сложный эфир вводят в суточной дозе, варьирующей в диапазоне от 30 до 90 мг.3. The method according to claim 2, in which the compound, or its salt, or ester is administered in a daily dose ranging from 30 to 90 mg. 4. Способ по любому из пп.1-3, в котором соединение, или его соль, или сложный эфир вводят перорально или трансдермально.4. The method according to any one of claims 1 to 3, in which the compound, or its salt, or ester is administered orally or transdermally. 5. Применение соединения, (деаминогидрокси)торемифена, или его фармацевтически приемлемой соли, или сложного эфира, или метаболита для изготовления фармацевтической композиции для лечения сухости влагалища или половой дисфункции у женщин во время или после менопаузы.5. The use of a compound, (deaminohydroxy) toremifene, or a pharmaceutically acceptable salt or ester or metabolite thereof, for the manufacture of a pharmaceutical composition for treating vaginal dryness or sexual dysfunction in women during or after menopause. 6. Применение по п.5, при котором соединение, или его соль, или сложный эфир вводят в суточной дозе, варьирующей в диапазоне от 25 до 100 мг.6. The use according to claim 5, in which the compound, or its salt, or ester is administered in a daily dose ranging from 25 to 100 mg. 7. Применение по п.6, при котором соединение, или его соль, или сложный эфир вводят в суточной дозе, варьирующей в диапазоне от 30 до 90 мг.7. The use according to claim 6, in which the compound, or its salt, or ester is administered in a daily dose ranging from 30 to 90 mg. 8. Применение по любому из пп.5-7, при котором соединение, или его соль, или сложный эфир вводят перорально или трансдермально.8. The use according to any one of claims 5 to 7, wherein the compound, or its salt, or ester is administered orally or transdermally.
RU2003105159/14A 2000-07-21 2001-05-02 Method for treating climacteric disorders in women either during or after menopause RU2268035C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/625,199 US6245819B1 (en) 2000-07-21 2000-07-21 Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
US09/625,199 2000-07-21

Publications (2)

Publication Number Publication Date
RU2003105159A true RU2003105159A (en) 2004-08-27
RU2268035C2 RU2268035C2 (en) 2006-01-20

Family

ID=24504996

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003105159/14A RU2268035C2 (en) 2000-07-21 2001-05-02 Method for treating climacteric disorders in women either during or after menopause

Country Status (30)

Country Link
US (5) US6245819B1 (en)
EP (1) EP1305014B1 (en)
JP (2) JP5575351B2 (en)
KR (1) KR100880564B1 (en)
CN (1) CN1287775C (en)
AT (1) ATE300289T1 (en)
AU (2) AU5844901A (en)
BG (1) BG65943B1 (en)
BR (1) BR0112659A (en)
CA (1) CA2416480C (en)
CY (1) CY1105370T1 (en)
CZ (1) CZ299439B6 (en)
DE (1) DE60112301T2 (en)
DK (1) DK1305014T3 (en)
EE (1) EE05344B1 (en)
ES (1) ES2241819T3 (en)
HR (1) HRP20030024A2 (en)
HU (1) HU229361B1 (en)
IL (1) IL153823A (en)
MX (1) MXPA03000378A (en)
NO (1) NO329954B1 (en)
NZ (1) NZ524181A (en)
PL (1) PL202654B1 (en)
PT (1) PT1305014E (en)
RU (1) RU2268035C2 (en)
SI (1) SI1305014T1 (en)
SK (1) SK287096B6 (en)
UA (1) UA74386C2 (en)
WO (1) WO2002007718A1 (en)
ZA (1) ZA200300342B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
DE60131644T2 (en) 2000-05-09 2008-10-30 Nitromed, Inc., Lexington INFRARED THERMOGRAPHY AND TREATMENT OF SEXUAL DYSFUNCTIONS
US6245819B1 (en) * 2000-07-21 2001-06-12 Hormos Medical Oy, Ltd. Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
PT1509215E (en) * 2002-06-06 2007-01-31 Hormos Medical Ltd Treatment or prevention of urogenital atrophy and its symptoms in women
US20060004088A1 (en) * 2002-10-22 2006-01-05 Oct Inc. Furan derivatives for preventing and curing osteoporosis and pharmaceutical compositions containing the same
US20040248989A1 (en) * 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US20050187302A1 (en) * 2004-02-23 2005-08-25 Hormos Medical Corporation Method for treatment or prevention of osteoporosis in individuals with high bone turnover
US8642079B2 (en) * 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
US8758821B2 (en) 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene
CA2565134C (en) * 2004-05-04 2013-05-21 Veli-Matti Lehtola Novel oral formulations of ospemifene
KR100734942B1 (en) 2007-01-02 2007-07-03 김재현 Dietary Supplements Effective in Women's Menopausal Syndrome
US7504530B2 (en) * 2007-02-14 2009-03-17 Hormos Medical Ltd. Methods for the preparation of fispemifene from ospemifene
JP5363344B2 (en) 2007-02-14 2013-12-11 ホルモス メディカル リミテッド Process for the preparation of triphenylbutene derivatives useful for therapy
US20080293683A1 (en) * 2007-05-24 2008-11-27 University Of Kansas Medical Center Hormone Replacement Therapy
RU2535112C2 (en) * 2012-09-19 2014-12-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Дагестанская государственная медицинская академия министерства здравоохранения и социального развития" Method of treating climacteric and urogenital disorders in women in postmenopause at background of hypothyroidism
WO2014060639A1 (en) 2012-10-19 2014-04-24 Fermion Oy A process for the preparation of ospemifene
MX2017011469A (en) 2015-03-10 2018-01-23 Shionogi Inc Solid dispersions.
JP2018512450A (en) * 2015-03-19 2018-05-17 ウェンディ アン エプスタインＥＰＳＴＥＩＮ， Ｗｅｎｄｙ Ａｎｎｅ Compounds and dosage forms for treating female sexual disorders
RU2636619C1 (en) * 2017-02-20 2017-11-24 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации Method for vaginal atrophy treatment in women in postmenopause considering vaginal epithelium and microbiocenosis state

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352699A (en) 1992-04-30 1994-10-04 University Of Massachusetts Medical Center Use of retinioc acid to treat vaginal atrophy
US5461064A (en) 1993-12-21 1995-10-24 Eli Lilly And Company Methods of inhibiting atrophy of the skin and vagina
GB9418067D0 (en) 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
US5747059A (en) 1996-01-11 1998-05-05 Novo Nordisk A/S Atrophy of skin/mucous membrane
GB9604577D0 (en) * 1996-03-04 1996-05-01 Orion Yhtymae Oy Serum cholesterol lowering agent
CO5271697A1 (en) * 2000-01-12 2003-04-30 Pfizer Prod Inc COMPOSITIONS AND PROCEDURES FOR THE TREATMENT OF AFFECTIONS THAT RESPOND TO AN INCREASE OF TESTOSTERONE
AU2991301A (en) 2000-01-28 2001-08-07 Endorecherche Inc. Selective estrogen receptor modulators in combination with estrogens
US20010034340A1 (en) 2000-03-20 2001-10-25 American Home Products Corporation Hormone replacement therapy
US6245819B1 (en) * 2000-07-21 2001-06-12 Hormos Medical Oy, Ltd. Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause

Similar Documents

Publication Publication Date Title
RU2003105159A (en) METHOD FOR TREATING CLIMACTERIC DISORDERS IN WOMEN DURING OR AFTER MENOPAUSE
CA2416480A1 (en) Method for the treatment of climacteric disorders in women during or after the menopause
US6051594A (en) Methods and formulations for modulating the human sexual response
EP0980245B1 (en) Use of misoprostol or/and misoprostol acid for the treatment of erectile dysfunction
US4590213A (en) Anti-anxiety method
JPH08231387A (en) Pharmaceutical composition for treating hypothalamic amenorrhea in a female mammal without depression
JP2005516913A5 (en)
CA2291160C (en) Combination therapy for modulating the human sexual response
JPH10147529A5 (en)
RU97120700A (en) NEW PHARMACOLOGICAL APPLICATION OF ANTAGONISTS A-II RECEPTOR
RU2002129298A (en) APPLICATION OF GALANTAMINE FOR THE TREATMENT OF PSYCHONEUROLOGICAL BEHAVIOR ASSOCIATED WITH ALZHEIMER'S DISEASE
RU2000125572A (en) NEW SET OF INTERVENTIONS
IE903945A1 (en) Therapeutic agents
RU2002129903A (en) A SOLID PHARMACEUTICAL COMPOSITION FOR ORAL USE CONTAINING A BISPHOSPHONIC ACID DERIVATIVE
HU220068B (en) Process for producing pharmaceutical preparations containing atipamezole for treatment impotence
US20240358712A1 (en) Compositions and methods for improving sexual sensory disorders
US20030207891A1 (en) Combination therapy for modulating the human sexual response
US20020115704A1 (en) Treatment method
Coutinho Vaginal Pills: Systemic Contraception Induced by Vaginal Administration
RU2001128509A (en) METHOD FOR TREATING NEURODEGENERATION
TH78435A (en) The crystalline form of the eprinone showing a high dissolution rate.
HK1028197B (en) Combination therapy for modulating the human sexual response
MXPA99010400A (en) Combination therapy for modulating the human sexual response